7.21
-0.1621(-2.20%)
Currency In USD
| Previous Close | 7.37 |
| Open | 7.38 |
| Day High | 7.51 |
| Day Low | 7.23 |
| 52-Week High | 14.38 |
| 52-Week Low | 5.81 |
| Volume | 176,613 |
| Average Volume | 439,543 |
| Market Cap | 486.35M |
| PE | 242.36 |
| EPS | 0.03 |
| Moving Average 50 Days | 6.73 |
| Moving Average 200 Days | 8.93 |
| Change | -0.1 |
If you invested $1000 in Bioventus Inc. (BVS) since IPO date, it would be worth $378.49 as of August 18, 2025 at a share price of $7.271. Whereas If you bought $1000 worth of Bioventus Inc. (BVS) shares 3 years ago, it would be worth $858.41 as of August 18, 2025 at a share price of $7.271.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference
GlobeNewswire Inc.
Aug 07, 2025 8:15 PM GMT
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will participate in a fireside cha
Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity
GlobeNewswire Inc.
Aug 04, 2025 12:00 PM GMT
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it has entered into a $400 million Senior Secured Credit Agreement
Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
GlobeNewswire Inc.
Jul 30, 2025 11:30 AM GMT
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both Tal